Clinical Trials Directory

Trials / Conditions / Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

7 registered clinical trials studyying Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.

StatusTrialSponsorPhase
Active Not RecruitingStudy of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Ac
NCT06054113
AmgenPhase 2
Active Not RecruitingStudy of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refr
NCT06253663
Kite, A Gilead CompanyPhase 2
CompletedA Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relap
NCT02614066
Kite, A Gilead CompanyPhase 1 / Phase 2
CompletedStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Re
NCT02625480
Kite, A Gilead CompanyPhase 1 / Phase 2
CompletedStudy of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT02412306
AmgenPhase 1 / Phase 2
TerminatedBlinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic
NCT02013167
AmgenPhase 3
No Longer AvailableExpanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precurso
NCT02187354
Amgen—